BetterLife Pharma (BETRF) Cash from Discontinued Operations (2019 - 2026)

BetterLife Pharma's Cash from Discontinued Operations history runs 8 years deep, the most recent figure standing at 174521.91 for Q2 2026.

• In Q2 2026, Cash from Discontinued Operations fell 1843.41% year-over-year to 174521.91; the TTM figure through Apr 2026 stood at 1850317443892.66 (down 24.5% YoY), while the FY2021 annual figure was 5360015951102.29, up 9.92% from the prior year.
• Cash from Discontinued Operations for Q2 2026 stood at 174521.91, down from 135772709590.3 in the prior quarter.
• The five-year high for Cash from Discontinued Operations was 1001366554678.94 in Q2 2023, with the low at 2379730510378.91 in Q3 2023.
• The 5-year median for Cash from Discontinued Operations is 174521.91 (2026), against an average of 400271725029.7.
• The sharpest annual moves came in 2022 and 2023: Cash from Discontinued Operations tumbled 13963814.82% in 2022, then jumped 415.33% in 2023.
• BetterLife Pharma's Cash from Discontinued Operations stood at 1669378669191.26 in 2022, then surged by 92.0% to 133601442707.79 in 2023, then plunged by 1386.58% to 1986089988971.42 in 2024, then jumped by 106.84% to 135772709590.3 in 2025, then plunged by 100.0% to 174521.91 in 2026.
• Business Quant data shows BETRF's Cash from Discontinued Operations at 174521.91 in Q2 2026, 135772709590.3 in Q3 2025, and 10010.37 in Q2 2025.